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Transfection of the skin by local gene delivery, as
well as widespread transfection of systemic tissues
following intravenous injection of cationic liposome/
DNA complexes have been reported. Here, we show
that surgically wounded mouse skin can be trans-
fected either by local injection of DNA alone or by
intravenous injection of optimized cationic lipo-
some/DNA complexes; however, direct cutaneous
injection produces much higher levels of gene
expression in the skin, which is targeted to dermal
and subdermal layers. High levels of chlorampheni-
col acetyltransferase activity were present from 3 h to
2 wk following direct injection of a gene expression
plasmid into wounded skin and were maintained at
detectable levels up to 8 wk after injection. Expres-
sion of transferred chloramphenicol acetyltransferase
as well as b-GAL genes was localized to ®broblasts,
macrophages, and adipocytes as determined by
histochemistry and immunohistochemistry. Further-
more, local injection of a human granulocyte-
colony-stimulating factor gene expression plasmid
produced high levels of the biologically relevant
human granulocyte-colony-stimulating factor protein
in wounded mouse skin. This ef®cient and simple
method of site-speci®c gene transfer into wounds
may lead to the development of cutaneous gene
therapy directed against disorders of abnormal cuta-
neous wound healing. Key words: cationic liposomes/
cutaneous gene transfer/gene therapy/wound healing. J
Invest Dermatol 116:131±135, 2001
T
he skin is in many ways an ideal target site for gene
delivery. It is readily accessible, and gene expression
may be restricted not only to the skin (potentially
avoiding nonspeci®c toxicity), but also to speci®c
layers and cell types within it (Greenhalgh et al, 1994).
The site of cutaneous gene expression will depend on the route of
gene delivery. In the skin, at least three different routes must be
considered: (i) topical application; (ii) intradermal injection; and
(iii) systemic delivery. The ®rst two approaches are of natural
importance as local/regional treatment strategies. Some of the most
serious dermatologic diseases that could bene®t from gene therapy
however, have both widespread cutaneous involvement and
extracutaneous involvement. Therefore, successful treatment of
these diseases may require systemic delivery that can achieve
ef®cient gene transfer to the skin.
Gene delivery to the skin has been accomplished by several
different approaches. These include topical application of non-
cationic liposome±DNA complex (Li and Hoffman, 1995), cationic
liposome±DNA complex (Nabel et al, 1993; Alexander and
Akhurst, 1995; Yu et al, 1999), particle-mediated (gene gun)
(Yang et al, 1990; Benn et al, 1996) and puncture-mediated (Ciernik
et al, 1996) gene transfections, and viral approaches (Setoguchi et al,
1994). Gene products have been detected in a number of cell types,
including basal keratinocytes, following epithelial cells, sebaceous
gland cells and dermal ®broblasts and dermal macrophages after
gene delivery.
Poor wound healing has been related to many factors, such as
radiotherapy (Miller and Rudolph, 1990), steroids (Di Rosa et al,
1986), ultraviolet radiation (Davidson et al, 1991), and micro-
vascular diseases (Ehrlichman et al, 1991). In these conditions,
neutropenia and neutrophil dysfunction have been found to
predispose to bacterial infection and have been associated with
delayed wound healing. Granulocyte-colony-stimulating factor
(G-CSF), a white blood cell hematopoietic growth factor,
upregulates the production of polymorphonuclear neutrophils
(PMN) (Anderlini et al, 1996). Importantly, in addition to
promoting the production of PMN, there is increasing evidence
that G-CSF may signi®cantly enhance PMN function (Betsuyacu
et al, 1999). Favorable effects of treating cutaneous wound sites with
recombinant G-CSF have been reported (Yalcin et al, 1997; Harada
et al, 1998). Recently, administration of recombinant human G-
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CSF (hG-CSF) has been reported to accelerate wound healing in a
patient with a persistent pharyngocutaneous ®stula following
laryngectomy (Cody et al, 1999). Therefore, it is reasonable to
hypothesize that topical delivery of therapeutically relevant genes to
wounded skin may help accelerate wound healing, thus potentially
reducing the high cost associated with recombinant protein
administration. In this study, we ®rst assessed the ef®ciency, time
course, and localization of gene expression following both local and
systemic gene delivery with either plasmid DNA alone or with
cationic liposome DNA complexes (CLDC) speci®cally to sites of
wounded skin. We then successfully delivered plasmid DNA
coding the hG-CSF gene into surgical wound sites, resulting in
signi®cant G-CSF expression.
MATERIALS AND METHODS
Plasmids, liposomes, and complexes The hCMV chloramphenicol
acetyltransferase (CAT) plasmid, p4119, the hCMV-b-GAL plasmid,
pCMVb, and the hCMV-hG-CSF plasmid have all been described
previously (Liu et al, 1995, 1997). Plasmid DNA was puri®ed and DNA
quantitated as previously described (Liu et al, 1995). Multilamellar
liposomes containing the cationic lipid 1-[2-(9(2)-Octadecencyloxy)-
ethyl]-2-[S(2)-heptadecenyl]-3-(2-hydroxyethyl)-imidazolinium chloride
(Solodin et al, 1995) in a 1 : 1 molar ratio with cholesterol were prepared
as previously described (Liu et al, 1997). Complexes of the liposomes with
plasmid were prepared as previously described (Liu et al, 1995).
Animal studies Two month old female ICR mice obtained from
Simonsen Labs (Gilroy CA), were used in all experiments. For skin
injection, in order to mimic a surgical wound, mice were ®rst anesthetized
by metofane inhalation, their backs shaved and disinfected with 70%
ethanol, and then a 1 cm long, full thickness surgical incision was made at
four individual sites on the dorsum of the back of each animal. Immediately
thereafter, 25 mg of the expression plasmid per wound, either uncomplexed
or as CLDC, was injected in 50 ml 5% wt/vol glucose into the wound edges
of each of the four wound sites on each animal in groups of two, using a
0.5 ml syringe and a 28.5G needle. Wounds were closed using a metal clip.
For intravenous injection (tail vein), mice in groups of four each received
60 mg of plasmid DNA, either uncomplexed or as CLDC, in 200 ml 5% wt/
vol glucose. The mice were killed in a CO2 chamber, and skin samples as
well as liver, spleen, heart, lungs, and lymph nodes were harvested at 0
(control), 1, 3, 6, and 24 h and 1, 2, 5, and 8 wk after injection.
Tissues were processed and analyzed for CAT enzymatic activity as
previously described (Liu et al, 1995), except that the [14C]-labeled
chloramphenicol±tissue extract mixture was allowed to react for 2 rather
than 8 h. Tissues were analyzed for hG-CSF protein by enzyme-linked
immunosorbent assay (Liu et al, 1995). Histochemical staining for b-GAL
activity (Liu et al, 1997), and immunohistochemical staining for CAT
antigen (Zhu et al, 1993) were each performed as described previously.
Statistical signi®cance of differences between the different levels of
expression was assessed by a two-sided Student's test.
RESULTS AND DISCUSSION
We ®rst determined dose±response relationships between the
amount of DNA injected and the level of CAT gene expression in
skin, 24 h following local cutaneous injection into wound sites of
CLDC containing from 5 mg to 200 mg of a CMV-CAT plasmid at
a 2 : 1 DNA/lipid ratio (mg DNA/nmole lipid) (Fig 1a). We found
Figure 1. CAT expression in mice following injection of p4119, a
CMV-CAT expression plasmid. (a) DNA dose-gene expression
response relationships in mice receiving local cutaneous injection of
CLDC. CAT activity in skin was determined 24 hours after local cutaneous
injection per wound of 0, 5, 25, 50, 75, 100, or 200 mg of a CMV-CAT
plasmid (p4119) complexed to cationic liposomes at a ratio of 2 : 1 (mg
DNA:nmole lipid). The values shown are the mean of eight individual
samples per dose 6 SEM. (b) Time course of expression following local
injection of 25 mg per wound of p4119, either as DNA alone or as CLDC.
The values shown are the mean of eight individual samples per time point
6 SEM. CAT activity in skin extracts (c), or in lung, heart, and liver
extracts (d), 24 h after local or intravenous injection of DNA alone or
CLDC. Groups of four mice received (i) CLDC containing 25 mg of p4119
at 2:1 or 1:16 (mg DNA/nmol lipid) ratios by direct injection into
wounded skin, or CLDC containing 60 mg of p4119 at 2:1 or 1:16 DNA/
lipid ratios by intravenous tail vein injection; or (ii) 25 mg per wound of
p4119 as naked DNA, injected into cutaneous wound sites; or (iii) 60 mg of
p4119 alone by intravenous tail vein injection. All mice were killed 24 h
after injection.
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that DNA doses of 5 mg injected per wound site produced highly
signi®cant levels of CAT activity (p< 0.0005 vs control mice). CAT
activity was present at peak levels at injected DNA doses > 25 mg.
Although the 5 mg DNA dose produced CAT activity at
approximately 75% of maximal levels, unless speci®cally stated,
we used 25 mg plasmid DNA per wound for all subsequent
experiments, in order to maximize the levels of gene expression
achieved. We also established that the level of transfection in
wounded skin was comparable with that produced in normal skin
of mice (data not shown), indicating that the presence of a surgical
wound site did not noticeably affect the expression of genes
injected into mouse skin. Examination of the effect of the DNA/
lipid ratio on transfection levels demonstrated that optimal
transfection occurs when the DNA is not complexed with lipid;
however, complexing with lipid does not reduce transfection levels
at ratios up to 2 mg DNA per nmol total lipid. Above this ratio, the
presence of lipid progressively suppresses transfection levels (data
not shown). This is in direct contrast to the effects of CLDC on the
ef®ciency of gene transfer and expression following intravenous
delivery of DNA (Zhu et al, 1993; Liu et al, 1995); however, it is
consistent with the ef®cient transfection of muscle tissue produced
by naked DNA (Wolff et al, 1990).
We next determined the time course of CAT gene expression
following wound injection with 25 mg per wound of a CMV-CAT
expression plasmid, either as DNA alone or as CLDC (DNA/lipid
ratio of 2 mg DNA per nmol total lipid). We found that signi®cant
levels of CAT activity were present in wounded skin as early as 3 h
after local injection (Fig 1b). Peak levels were present by 6 h, and
persisted for approximately 1 wk. Signi®cant CAT activity was
present for at least 2 wk. All CAT gene-treated groups, killed from
3 h to 2 wk following injection, showed signi®cantly higher levels
of CAT activity (p< 0.0005) than control animals. At the 5 and
8 wk time points, expression approached baseline levels, although
CAT activity in both the DNA alone and CLDC groups was still
signi®cantly (p< 0.05) above control levels (Fig 1b). The levels of
CAT activity produced by DNA alone and by CLDC at a DNA/
lipid ratio of 2 mg DNA per nmol of lipid or greater were similar at
all time points assayed. Thus, complexation of DNA with cationic
lipids did not enhance transfection ef®ciency in wounded skin at
any time point.
We then compared the amount of CAT activity produced in
wounded skin and in systemic organs, following either local
cutaneous injection with 25 mg per wound of the CMV-CAT
expression plasmid, either as DNA alone or as CLDC in a 2:1 DNA/
lipid ratio (2 mg DNA per nmol total lipid), or by intravenous
injection of 60 mg of CMV-CAT, either alone or complexed to
cationic liposomes at either 2:1 or 1:16 DNA/lipid ratios. Local
injection of either DNA alone or in CLDC produced high levels of
CAT gene expression in the skin (Fig 1c), but did not produce
signi®cant levels of CAT activity in extracutaneous tissues (Fig 1d).
Intravenous injection of either CLDC (2:1) or DNA alone produced
minimal expression in the skin (Fig 1c). Local injection of CLDA at a
1:16 DNA/lipid ratio produced only background levels in extra-
cutaneous tissues (Fig 1d), whereas intravenous injection of the same
material produced high levels of CAT gene expression in the heart,
lung, and liver (Fig 1d) as well as signi®cant levels of gene expression
(p< 0.005 vs controls) in the skin (Fig 1c).
Using enzyme histochemistry and immunohistochemistry, gene
expression was localized within mouse skin following injection of
CMV-b-GAL or CMV-CAT expression plasmids directly into
wound sites. We found that b-GAL and CAT expression were
most intense within discrete areas near the dermal±subdermal
interface corresponding to injection sites (Fig 2a). Within these
areas, staining of adipocytes was most prominent (Fig 2c), followed
Figure 2. Localization of b-galactosidase or
CAT expression following plasmid injection
into wounded skin. (a) Macroscopic aspect of
wounded skin. Blue foci near wound edges
demonstrate the b-galactosidase gene product, pre-
sent in sites where CMV-b-galactosidase expres-
sion plasmid was injected intradermally 24 h
earlier. (b) In a control area of wounded skin,
injected with CMV-CAT expression plasmid
intradermally 24 h earlier, no b-galactosidase activ-
ity is seen. Both specimens were exposed to X-gal
solution to disclose b-galactosidase activity. (c) A
non-counter stained histologic section (303)
obtained from (a) demonstrates the presence of
blue b-galactosidase activity in the lower dermis
and subcutis. The most intensely staining cells
within these sites are predominately adipocytes. (d)
Histologic section (3003) of the dermis near a
wound margin from a mouse injected intraderm-
ally 24 h earlier. The red stained cells containing
CAT-antigen, as detected immunohistochemically.
Morphologically, these cells are consistent with
histiocytes and, less frequently, with ®broblasts. (e)
Histologic section (3003) of skin from a wound
margin from a mouse injected intradermally 24 h
earlier with a CMV-luciferase expression plasmid
(control) that was concurrently assayed for CAT-
antigen expression. CAT-antigen is not detectable.
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by positive immunostaining of individual of individual cells
consistent with histiocytes and occasional ®broblasts near wound
margins (Fig 2d). There was no evidence of gene expression in the
epidermis.
Finally, we injected the gene coding for the therapeutically
relevant hG-CSF protein directly into wounded skin. We chose to
use the hG-CSF gene because recombinant hG-CSF protein is now
commonly administered to immunosuppressed human patients
(Kearns et al, 1993) and because we use an hG-CSF enzyme-linked
immunosorbent assay that does not detect murine G-CSF activity
(Liu et al, 1993), thus avoiding background interference. An hG-
CSF expression plasmid was injected either as DNA alone or as
CLDC at a 2:1 ratio and the wound site harvested 24 h later.
Injection of the hG-CSF plasmid as CLDC produced 395 6 274 pg
(SD) or hg-CSF protein per mg of tissue. Injection of the hG-CSF
plasmid alone produced 241 6 112 pg G-CSF per mg tissue,
whereas neither uninjected nor mock-injected control mice
showed detectable (< 10 pg per mg tissue) hG-CSF activity. The
hG-CSF gene-treated groups showed signi®cantly higher levels of
hG-CSF protein in the skin (p< 0.025) than did the control groups.
Thus, we have shown that wounded skin can be transfected
either by local injection of naked DNA or CLDC or by
intravenous injection of optimized CLDC. The former produces
high levels of gene expression localized to the dermal and
subdermal layers of the skin, whereas the latter produces both
lower levels of gene expression within wounded skin as well as
generalized gene expression in extracutaneous tissues. The favor-
able time course of gene expression (peak levels lasting from 6 h to
1 wk postinjection) as well as the high level expression of the
therapeutically relevant hG-CSF gene produced by local injection
of plasmid DNA or CLDC suggest that this approach may become
clinically useful for the treatment of dysfunctional wound healing,
as well as for other genetic and acquired cutaneous diseases.
Delayed wound healing has represented a major clinical problem
for some patients receiving radiotherapy, chemotherapy, steroids,
and/or ultraviolet radiation, as well as in patients with micro-
vascular disorders, such as diabetes. Among the many factors
thought to interfere with wound healing in these patients,
neutropenia, and neutrophil dysfunction, leading to severe or
chronic bacterial infection, are considered to be important
predisposing factors. Several strategies to modulate skin wound
healing have already been reported (Young, 1988; LaVan and
Hunt, 1990; Violaris and Bridger, 1990; Miller and Rudolph, 1990,
Vogt et al, 1994; Andree et al, 1994; Benn et al, 1996), with positive
but limited effects. To date, poor wound healing remains a dif®cult
clinical problem. Therefore, further investigations are required to
accelerate wound healing in these patients.
One way to accelerate problematic wound healing is to
strengthen host defense systems, in order to prevent and/or treat
bacterial infection. G-CSF, the principal hematopoietic growth
factor that stimulates PMN production, has been proved to be
ef®cient in treating neutropenia in a number of clinical settings.
Recent research has shown that, in addition to increasing the
number of PMN, G-CSF may also play an important part in
multiple aspects of enhancing PMN function. These include: (i)
enhancing CD11b (Hakanson et al, 1997) and FcgRi expression
(Gericke et al, 1995); (ii) enhancing PMN adhesion (Hakanson et al,
1997); (iii) phagocytosis (Hoglund et al, 1997); (iv) degranulation
(Xu et al, 1996); and (v) chemokinesis (Yong 1996). Furthermore,
G-CSF may also modulate peripheral mature PMN activation
(Metcalf et al, 1996) and regulate PMN chemokine responsiveness
(Betsuyacu et al, 1999). Subcutaneous application of G-CSF has
been found to be effective in reducing bacterial translocation due to
burn wound sepsis (Yalcin et al, 1997). Finally, G-CSF has been
used clinically to promote wound healing successfully in a
neutropenic patient after head and neck surgery (Cody et al, 1999).
In this study, we achieved high-level G-CSF expression
following local cutaneous injection of either plasmid DNA coding
for G-CSF alone or in CLDC. In addition, we have recently
developed a novel, Epstein±Barr virus-based long-term expression
vector that produces therapeutic levels of hG-CSF gene expression
for at least 2 mo after a single injection in mice of CLDC
containing the hG-CSF gene into mice (data not shown). This
vector may allow us to investigate further skin gene therapy for
poor wound healing, targeting other genes that have potential
applications for skin disorders. In addition, the costs involved in
upscaling the use of cutaneous delivery of DNA plasmids for
potential therapeutic approaches in human patients with cutaneous
disorders may be substantial. The use of novel expression vectors
that produce more durable and/or higher levels of expression of
delivered genes may make nonviral, plasmid-based approaches
more cost-effective, when compared with the signi®cant costs
involved in preparing either recombinant viral vectors or
recombinant proteins for cutaneous therapy studies. Combining
expression plasmids that produce longer durations of gene
expression together with lower injected doses of DNA that still
produce signi®cant levels of cutaneous gene expression (see Fig
1a), may make this approach feasible from a cost basis.
In summary, we have demonstrated that direct intradermal
injection of multiple plasmid DNAs into wound sites consistently
results in site-speci®c gene expression that is targeted to dermal and
subdermal layers as well as a number of different cell types. We
have also shown that this approach resulted in high levels of
therapeutically relevant hG-CSF gene expression, following local
injection of either plasmid DNA alone or CLDC. In contrast to
other gene transfer modalities, which are potentially infectious and/
or immunogenic as viral vectors are used, or which require
sophisticated and expensive technical support, the injection of
naked DNA is not only ef®cient, but simple, safe, and inexpensive.
These properties are also largely consistent with the requirements
for a clinically applicable cutaneous gene transfer system. Given the
experience with existing wound repair models, it is therefore
conceivable that effective cutaneous gene therapy approaches for
the many clinical problems associated with abnormal wound
healing are feasible.
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